fashion -WSS

fashion

author：knowledge 2025-09-06 03:55:18 - browse：367

Walmart seems poised to increase its health care footprint by buying value-based senior care company ChenMed. Joe Raedle/Getty Images

Walmart seems poised to increase its health care footprint by buying value-based senior care company ChenMed, per reports from Bloomberg.

Experts largely hailed the rumored sale as a good buy, citing the management of chronic conditions in the Medicare Advantage population through primary care, ChenMed’s specialty, as an area with huge innovation and cost savings over the last 10 years.

“If you’re going to purchase primary care in the senior space, there’s no one better than ChenMed. The only other one that might be better or equivalent would be Oak Street, but they were just purchased,” said Jon Kaplan, a senior partner at BCG. “In the world of great primary care practices to buy, in my top two are Oak Street and ChenMed, and one of them’s available, one’s not.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： BioMarin wins approval for gene therapy to treat hemophilia A
Next article： Gene therapy has helped boys walk. Can scientists keep it that way?

focus

WSS

The Biogen Aduhelm mess could happen again

What is the Wagner Group? The 'brutal' Russian military unit in Ukraine

Donald Trump's relentless attacks on special counsel Jack Smith

The story of mRNA: From a loose idea to a tool that may help curb Covid

What would happen to your eyes if you looked at the solar eclipse?

What’s missing from the debate over nursing home staff minimums

entertainment

fashion

Wikipedia

In Memoriam: Notable people who died in 2023

#NeedHerScience: shining a light on gender disparities in medicine

Heart attack and stroke risk calculators need revising

With FDA staff opposed to Sarepta therapy, top official intervened

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Gritstone Bio's cancer vaccine test, and more on Novartis' deal

The cancer drug shortage isn’t new — and neither are the solutions

Adopting new red light myopia treatments may be short

Guidelines to prevent youth baseball injuries need more muscle

Gritstone Bio's cancer vaccine test, and more on Novartis' deal

Wikipedia

Unique patient identifier: Experts argue the benefits, pitfalls

Problems with a popular proposal to regulate AI in health care

Devoted Health’s losses in Medicare Advantage persist

Cano Health’s bankruptcy is a warning for Medicare Advantage

The CDC's new social media misinformation war

Paxlovid study fails to answer questions over benefit for broader groups

focus

hotspot

focus

hotspot